The IMBrave150 phase III clinical trial resulted in the approval of the immunotherapy combination of Atezolizumab (anti-PD-L1) plus Bevacizumab (anti-VEGF) as a first-line systemic treatment for advanced disease and the first significant change in HCC patient treatment for over a decade [3]. Here, CD274 is linked to hepatocellular carcinoma.